Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tekmira Pharmaceuticals has reported that its development partner Hana Biosciences has found promising interim Phase I clinical data for cancer product candidate Alocrest.
Subscribe to our email newsletter
Hana Biosciences’ data has demonstrated anti-tumor activity in three of eleven patients with refractory solid tumors and has also showed that Alocrest was relatively well tolerated over multiple cycles of therapy.
The early clinical data indicated that Alocrest, a drug consisting of the FDA-approved drug vinorelbine encapsulated inside the optisomal drug delivery technology, may be extending circulation time and tolerability as compared to free vinorelbine. The interim results illustrate the potential of Alocrest’s anti-cancer activity among patients with advanced, difficult-to-treat cancers.
Alocrest, Marqibo and Brakiva are chemotherapy product candidates that Tekmira licensed to Hana Biosciences in 2006.